Downregulated SOX9 mediated by miR‑206 promoted cell apoptosis in Legg-Calvé-Perthes disease

Luo,Junzhong; Han,Jiuhui; Li,Yazhou; Liu,Yuchang

doi:10.3892/ol.2017.7373

Downregulated SOX9 mediated by miR‑206 promoted cell apoptosis in Legg-Calvé-Perthes disease

Authors:
- Junzhong Luo
- Jiuhui Han
- Yazhou Li
- Yuchang Liu
View Affiliations

Affiliations: Department of Pediatric Orthopaedics, The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei 050051, P.R. China
Published online on: November 8, 2017 https://doi.org/10.3892/ol.2017.7373
Pages: 1319-1324

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Legg-Calvé-Perthes disease (LCPD) commonly onsets in adolescents, and threatens their health. However, the potential mechanism underlying LCPD remains unclear. MicroRNA (miR)‑206 and SRY‑box 9 (SOX9) serve an important role in chondrocytes; however, their role in LCPD remains ambiguous. In the present study, whether miR‑206 and SOX9 mediated cell apoptosis in dexamethasone (DEX)‑induced LCPD was investigated. The chondrocytes of the LCPD and normal control group were isolated from clinical tissues. Reverse transcription‑quantitative polymerase chain reaction was used to evaluate the expression of miR‑206 and SOX9 mRNA. Western blotting was used to measure the protein level of SOX9. A combination of Annexin V‑fluorescein isothiocyanate flow cytometry was used to assess cell apoptosis. The association between miR‑206 and SOX9 was detected using a luciferase reporter assay. miR‑206 was overexpressed while SOX9 was downregulated in chondrocytes treated with DEX obtained from patients with LCPD. miR‑206 targeted SOX9 to regulate its expression. Overexpression of miR‑206 promoted cell apoptosis in TC28, while it was reversed by SOX9 overexpression. TC28 cells pretreated with DEX significantly promoted cell apoptosis, while cells transfected with miR‑206 inhibitor significantly reversed the effect; however, downregulated SOX9 abolished the effects of miR‑206 inhibitor. SOX9 mediated by miR‑206 possibly contributed to the pathogenesis of LCPD. The results of the present study suggest that miR‑206 and SOX9 function as important therapeutic targets for the future of clinical therapy.

View Figures

View References

1	Pathak-Bhatt K, Couterier R and Tobis JS: Poster 176: Legg-calve-perthes disease in a 9-Year-Old Girl: A clinical case report. Pm R. 2 Suppl:S812010. View Article : Google Scholar
2	Zhang C, Li Y, Cornelia R, Swisher S and Kim H: Regulation of VEGF expression by HIF-1α in the femoral head cartilage following ischemia osteonecrosis. Sci Rep. 2:6502012. View Article : Google Scholar : PubMed/NCBI
3	Murphey MD, Foreman KL, Klassen-Fischer MK, Fox MG, Chung EM and Kransdorf MJ: From the radiologic pathology archives imaging of osteonecrosis: Radiologic-pathologic correlation. Radiographics. 34:1003–1028. 2014. View Article : Google Scholar : PubMed/NCBI
4	Mata-Rocha M, Hernández-Sánchez J, Guarneros G, de la Chesnaye E, Sánchez-Tusié AA, Treviño CL, Felix R and Oviedo N: The transcription factors Sox5 and Sox9 regulate Catsper1 gene expression. FEBS Lett. 588:3352–3360. 2014. View Article : Google Scholar : PubMed/NCBI
5	Javier BM, Yaeger R, Wang L, Sanchez-Vega F, Zehir A, Middha S, Sadowska J, Vakiani E, Shia J, Klimstra D, et al: Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. Oncotarget. 7:50875–50882. 2016. View Article : Google Scholar : PubMed/NCBI
6	Tamamura Y, Katsube K, Mera H, Itokazu M and Wakitani S: Irx3 and Bmp2 regulate mouse mesenchymal cell chondrogenic differentiation in both a Sox9-dependent and-independent manner. J Cell Physiol. 232:3317–3336. 2017. View Article : Google Scholar : PubMed/NCBI
7	Cucchiarini M, Orth P and Madry H: Direct rAAV SOX9 administration for durable articular cartilage repair with delayed terminal differentiation and hypertrophy in vivo. J Mol Med (Berl). 91:625–636. 2013. View Article : Google Scholar : PubMed/NCBI
8	Cheah KSE, Au TYK, Wynn S, Tan TY and Yip RKH: Sox9 restrains chondrocyte to osteoblast lineage progression-implications for the pathogenesis of Campomelic Dysplasia. Proceedings of The 13th Annual Meeting of the International Society For Stem Cell Research (ISSCR 2015). Stockholm, Sweden. International Society For Stem Cell Research, Skokie, IL. pp. 2812015;
9	Oh CD, Yasuda H, Zhao W, Henry SP, Zhang Z, Xue M, de Crombrugghe B and Chen D: SOX9 directly regulates CTGF/CCN2 transcription in growth plate chondrocytes and in nucleus pulposus cells of intervertebral disc. Sci Rep. 6:299162016. View Article : Google Scholar : PubMed/NCBI
10	Godfrey AC, Xu Z, Weinberg CR, Getts RC, Wade PA, DeRoo LA, Sandler DP and Taylor JA: Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Breast Cancer Res. 15:R422013. View Article : Google Scholar : PubMed/NCBI
11	Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y and Dahiya R: Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One. 7:e510562012. View Article : Google Scholar : PubMed/NCBI
12	Boominathan L: The tumor suppressors p53, p63, and p73 are regulators of microRNA processing complex. PLoS One. 5:e106152012. View Article : Google Scholar
13	Liu G, Luo G, Bo Z, Liang X, Huang J and Li D: Impaired osteogenic differentiation associated with connexin43/microRNA-206 in steroid-induced avascular necrosis of the femoral head. Exp Mol Pathol. 101:89–99. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, Luo Y, Shi Y, Wang K and Ji G: miR-206 is down-regulated in breast cancer and inhibits cell proliferation through the up-regulation of cyclinD2. Biochem Biophys Res Commun. 433:207–212. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ciesla M, Marona P, Kozakowska M, Jez M, Seczynska M, Loboda A, Bukowska-Strakova K, Szade A, Walawender M, Kusior M, et al: Heme Oxygenase-1 Controls an HDAC4-miR-206 pathway of oxidative stress in rhabdomyosarcoma. Cancer Res. 76:57072016. View Article : Google Scholar : PubMed/NCBI
16	Beckmann R, Shaheen H, Kweider N, Ghassemi A, Fragoulis A, Hermanns-Sachweh B, Pufe T, Kadyrov M and Drescher W: Enoxaparin prevents steroid-related avascular necrosis of the femoral head. ScientificWorldJournal. 2014:3478132014. View Article : Google Scholar : PubMed/NCBI
17	Drescher W, Beckmann R, Kasch R, Pufe M, Knobe M, Kweider N, Hassenpflug J, Tingart M, Pufe T and Kadyrov M: Nitrate patch prevents steroid-related bone necrosis. J Orthop Res. 29:1517–1520. 2011. View Article : Google Scholar : PubMed/NCBI
18	Zeng M, Li ZY, Ma J, Cao PP, Wang H, Cui YH and Liu Z: Clarithromycin and dexamethasone show similar anti-inflammatory effects on distinct phenotypic chronic rhinosinusitis: An explant model study. BMC Immunol. 16:372015. View Article : Google Scholar : PubMed/NCBI
19	Li H, Li T, Fan J, Li T, Fan L, Wang S, Weng X, Han Q and Zhao RC: miR-216a rescues dexamethasone suppression of osteogenesis, promotes osteoblast differentiation and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT pathway. Cell Death Differ. 22:1935–1945. 2015. View Article : Google Scholar : PubMed/NCBI
20	Ghali O, Broux O, Falgayrac G, Haren N, van Leeuwen JP, Penel G, Hardouin P and Chauveau C: Dexamethasone in osteogenic medium strongly induces adipocyte differentiation of mouse bone marrow stromal cells and increases osteoblast differentiation. BMC Cell Biol. 16:92015. View Article : Google Scholar : PubMed/NCBI
21	Inose H, Ochi H, Kimura A, Fujita K, Xu R, Sato S, Iwasaki M, Sunamura S, Takeuchi Y, Fukumoto S, et al: A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci USA. 106:pp. 20794–20799. 2009; View Article : Google Scholar : PubMed/NCBI
22	Li J, Wang L, Liu Z, Zu C, Xing F, Yang P, Yang Y, Dang X and Wang K: MicroRNA-494 inhibits cell proliferation and invasion of chondrosarcoma cells in vivo and in vitro by directly targeting SOX9. Oncotarget. 6:26216–26229. 2015. View Article : Google Scholar : PubMed/NCBI